Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus CAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus CAPEX.
AMCINONIDE vs CAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."